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Background: Environmental epidemiology, when focused on the life course of exposure to a specific pollutant,
requires historical exposure estimates that are difficult to obtain for the full time period due to gaps in the historical
record, especially in earlier years. We show that these gaps can be filled by applying multiple imputation methods
to a formal risk equation that incorporates lifetime exposure. We also address challenges that arise, including choice
of imputation method, potential bias in regression coefficients, and uncertainty in age-at-exposure sensitivities.
Methods: During time periods when parameters needed in the risk equation are missing for an individual, the
parameters are filled by an imputation model using group level information or interpolation. A random component
is added to match the variance found in the estimates for study subjects not needing imputation. The process is
repeated to obtain multiple data sets, whose regressions against health data can be combined statistically to
develop confidence limits using Rubin’s rules to account for the uncertainty introduced by the imputations. To test
for possible recall bias between cases and controls, which can occur when historical residence location is obtained
by interview, and which can lead to misclassification of imputed exposure by disease status, we introduce an
“incompleteness index,” equal to the percentage of dose imputed (PDI) for a subject. “Effective doses” can be
computed using different functional dependencies of relative risk on age of exposure, allowing intercomparison of
different risk models. To illustrate our approach, we quantify lifetime exposure (dose) from traffic air pollution in an
established case–control study on Long Island, New York, where considerable in-migration occurred over a period
of many decades.
Results: The major result is the described approach to imputation. The illustrative example revealed potential recall
bias, suggesting that regressions against health data should be done as a function of PDI to check for consistency
of results. The 1% of study subjects who lived for long durations near heavily trafficked intersections, had very high
cumulative exposures. Thus, imputation methods must be designed to reproduce non-standard distributions.
Conclusions: Our approach meets a number of methodological challenges to extending historical exposure
reconstruction over a lifetime and shows promise for environmental epidemiology. Application to assessment of
breast cancer risks will be reported in a subsequent manuscript.
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Historical reconstruction of exposure offers the oppor-
tunity to cover periods of a person's life when they may
be most vulnerable [1,2], but data challenges may make
it difficult to attempt such a reconstruction for an epide-
miologic study. Despite these difficulties, long-term
assessment of residential exposure to pollutants is in-
creasingly being used in environmental epidemiology of
disease, particularly cancer [3-5]. As part of an effort in
a large-scale study of environmental exposures and
breast cancer [6], we wanted to add individualized inhal-
ation exposures of PAH from traffic emissions to a pre-
viously collected set of individualized PAH exposures
from diet and active/passive smoking. Within the cat-
egory of PAH air exposure, we focused on traffic emis-
sions because they are a major source of both indoor
and outdoor exposures to PAH, and often the largest
source in areas near cities, as has been confirmed in a
number of experimental studies [7-12]. However, it was
necessary to confront a number of methodological chal-
lenges before inhalation exposure from traffic could be
obtained over a lifetime and before it could be totaled
appropriately.
First, it was necessary to decide how to combine yearly
exposures over decades. There was no guarantee that
simply adding them to obtain a dose would capture pos-
sible differences in relative risk per unit of exposure at
different study-subject ages. We approached this chal-
lenge by computing “effective doses” assuming a range
of different functional dependencies on age of exposure.
Effective doses are computed by summing functions of
yearly exposure. Having a suite of effective doses avail-
able for use in regressions against health outcomes al-
lows for broad coverage of the possible age-sensitivities.
Second, it was necessary to deal with exposure before
study subjects arrived in the study area, as well as expos-
ure that occurred in years before desirable records on
emissions and traffic flows were available. A third chal-
lenge arose, because the earlier in time we went back to
estimate exposure, the greater the percentage we found
of missing residential information. To deal with these
two types of missing-data problems we propose the use
of multiple imputation, namely constructing a series of
data sets with missing parameters randomly drawn from
a set of predetermined values derived from an imput-
ation model. The resulting multiple data sets are then
available to be regressed against health outcomes. On
the positive side of this approach, random errors in re-
gression coefficients are reduced within an imputation
data set, because sample sizes are increased. On the
negative side, there is new variance in regression coeffi-
cients introduced when comparing results between im-
puted data sets. The net effect of these competing
tendencies on overall variance can be assessed usingRubin’s Rules or alternate formulations [13-15]. With
this combined variance in hand, confidence limits on re-
gression coefficients can be obtained that explicitly in-
clude uncertainty introduced by imputation of missing
values.
The fourth challenge we faced was a consequence of
limitations in the imputation process itself, namely the
vulnerability to increased risk of recall bias, when in-
formation needed to impute a missing dose component
is based in part on questionnaire answers obtained
from individual study participants. This can lead to
bias in regression coefficients and, therefore, the possi-
bility of finding false or hidden associations with
health outcome.
The quantity imputed is the portion of the total dose
accumulated during periods of missing location data or
missing emissions data. The percentage of the missing
component can vary in magnitude by study subject. Al-
though dealing with partially missing information
presented a challenge, it also offered an opportunity to
check the robustness of regressions with imputed data,
and thus test for recall bias. To this end, we introduce
the “percentage of dose imputed” (PDI) as a continuous
index that allows limiting analysis to groups of study
subjects depending on their degree of imputation. With
PDI limit set to 0, the analysis is a complete-case ana-
lysis. With the limit on PDI set to 100%, the full popula-
tion is analyzed. In this way, regression of health data
could be performed as a function of the limit on PDI to
see if the results were consistent as larger and larger
components of imputed dose were allowed for study
subjects. If there was consistency, then it would be rea-
sonable to extend the results of a complete-case analysis
to larger segments of the full population.
A fifth methodological challenge arose, because the
observed doses among the subjects with complete infor-
mation turned out to be right skewed: specifically in our
case–control study the 1% of women who had lived for a
long time near heavily trafficked intersections. This
presented a challenge to our imputing doses in such a
way as to properly populate “outlier” values. To deal
with this type of imputation challenge, we propose ap-
proaches that do not assume standard distributions;
moreover we recommend using more than one approach
to allow testing the sensitivity of the regression results
to the choice of imputation model.
All of these challenges are likely to be faced, to a lesser
or greater degree, when researchers contemplate studies
that require individualized historical exposures of adults
over a lifetime, or even a great portion of it. As a result
of all the potential difficulties, historical exposure is
often ignored and analysts look for associations with ex-
posures in recent periods when data are complete. How-
ever, doing so can introduce exposure misclassification,
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and the variation of exposure in place and time, with a
resulting tendency to bias results towards the null. Asso-
ciations can be missed [16]; and periods of greatest im-
portance for health effects go unnoticed [4]. One
approach to dealing with missing historical exposure
data is to restrict analysis to a subset of the study popu-
lation with complete data, but such a restriction can de-
crease sample size drastically and raises questions about
applicability of results to the entire study population.
Thus, it was of interest to explore new ways to accom-
plish multiple imputation in the historical context and
to find ways to test for recall bias.
We illustrate the approaches developed to deal with
the challenges using data from a population-based, case
control study of breast cancer on Long Island, New
York, a cancer for which a life-course approach to re-
search is strongly recommended [17].
Methods
Risk equation
Our ultimate goal is to obtain dose estimates that can be
used as predictor variables in logistic regression models
of disease risk in which log (odds of disease) is linear in





¼ Aþ β  Zcalc i; yð Þ þ Zimp i; yð Þ
  ð1Þ
In Eq. 1, pi is the probability of an individual, i, be-
coming a case in year, y. β is a regression coefficient.
Zcalc(i, y) is the exposure opportunity accumulated for
time periods when information is complete for individ-
uals, i, permitting individualized estimates. Zimp(i, y), is
an imputed dose for any time periods of interest when
information needed for an individualized exposure esti-
mate is lacking. Only the missing subcomponents of the
exposure model are imputed, so that as much physical
and biologic knowledge is retained. Zimp(i, y), by defin-
ition, will be zero for the set of subjects included in
complete-case analysis.
Covariates that represent known risk factors for the
disease under study, as well as possible confounding var-
iables, are implicitly included in A. The magnitude of
Zcalc(i, y) + Zimp(i, y) determines the risk that subject, i,
will become a case in year, y, arising from exposure ter-
minating in a given year, such as a year related to a bio-
logical state (e.g., menopause), or at the end of the study
period, which is the value chosen for our numerical
examples.
To account for different sensitivity to age of exposure,
the Z(i, y) terms in Equation 2 allow for more than a
simple sum over short-term exposure calculations.
Within the sum, each short-term calculation is multipliedby a “biological effectiveness” factor potentially dependent
on age at exposure and age of disease onset.
Z i; yð Þ ¼
Xystop
y0¼yb
E y0; ið Þ  B y0−yb; y−ybð Þ; ð2Þ
E(y’, i) is the short-term exposure at date, y′. The vari-
able, y, is the year of disease diagnosis. The sum in Eq. 2
is over the dates, y′, running from birth year, yb, to the
last date of exposure interest, ystop. B(y′-yb, y-yb) is a
relative risk that compares the effect of unit exposure at
age, y'-yb, to the effect at a standard age of exposure, say
1-years old. Thus, if a unit dose at age 10 will double the
risk of disease caused by a unit dose at age 1, the B-vari-
able for age 10 equals 2. In this way, the Z-terms, which
depend on B, can be called effective doses.
Subjects with the same Z-dose have the same in-
crease in log (odds of disease) compared to an unex-
posed person, no matter how their exposure was
distributed over time. Rather than define the baseline
of B as a single exposure in a particular year, the base-
line can be defined relative to a standard distribution of
exposure over a time period. To include birth-cohort
effects, for instance in a cohort study, the B-factor
would include a separate entry for birth year, yb, and be
written as B(y′-yb, y-yb, yb).
In this paper, we consider four functional forms for B,
distinguished by subscripts 1 through 4, which span a
wide range of possible age sensitivities:
B1: B = Constant;
B2: B is inversely proportional to square of age of onset,
which increases relative risk at young ages (as in best
mathematical fit to data for relative risk of breast
cancer following ionizing radiation exposure [2]);
B3: B vanishes except at peak historical exposure
(threshold model). (To work as a threshold model, B3
can be used in conjunction with a threshold step
function added to the risk equation.);
B4: B is negligible except in the last k-years of the study
(pure promoter model).
We note that a latency period can be implemented in
any of the above models simply by changing the stop
year in the summations.
The equation for effective dose, Eq. 2, involves a sum-
mation over a study subject’s entire life, but individual
values of each variable that are needed to compute the
sum are not usually completely available since birth. To
fill in the missing information, we replace variables at
various times with group level values. The time steps
over which emissions must be tracked in equation 2 de-
pends on the model being used to assign individualized
exposure estimates. The base unit might be months, or
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depending on disease and the nature of the short-term
exposure model. For instance, the natural starting unit
might be hours for a meteorological dispersion model
that tracks emissions that vary by hour of day and ac-
counts for the correlated meteorological conditions that
also change hour by hour, such as rainfall, wind speed,
and wind direction. Such an hourly model may be test-
able against hourly air concentration data collected at
monitoring stations [18,19]. As long as average emis-
sions per month do not change rapidly, it possible to do
the hourly summations once for each month of the year
and use the results for the same month in each year
without much loss in accuracy. Data averaged by month
is appropriate when movement of study subjects be-
tween residences is known by month of the year.
It is useful to separate the exposure, E(y′, i), in Eq. 2
into sums or products of terms that reflect the under-
lying model of exposure, so that terms needing imput-
ation can be separately identified. For a land use
regression model the natural separation might be a lin-
ear combination of terms, including air concentrations
at monitoring stations [20]. For a meteorological disper-
sion model, it would be natural to break E(y', i) into a
product of terms. Regardless of whether the separation
is a sum or product, whenever there is a time that a par-
ticular term or subpart is missing for an individual, it
will need to be imputed according to an imputation
model. In either case, random numbers are used in the
multiple imputation model as part of the process of
drawing parameter values from a predetermined set of
options.
For the traffic emission example, we assume organ
doses are linearly related to air concentrations and ex-
pand Eq. 2 as a product that reflects the underlying
physical process of tailpipe carcinogens being emitted
from vehicles and those carcinogens being transported
through the air to reach a residence:
E y0; ið Þ ¼ ε y0ð Þ  T y0ð Þ  D y0; rib y0cð Þ; ð3Þ
ε(y′) in Eq. 3 is the average emission per km from the
tailpipe of an average vehicle along the road network at
a particular date, y′, determined from average US values
[21]. T(y′), in Eq. 3, is the average number of vehicles
per km on an average road in the modeling area in the
year, y′. Since 1970 it has increased by a factor of 2.7 in
the entire U.S. [21]. D(y′, ri[y]), in Eq. 3, is the “disper-
sion function,” also called the “transfer function” [22]. It
relates emissions from the entire road network to expos-
ure at individual residences, ri. It is computed by track-
ing puffs of pollution as they change direction with
hourly-wind changes, as they expand at rates dependent
on meteorological conditions, as their concentrationdeclines due to depletion processes, and as they finally
arrive at residences.
D represents one hour’s exposure received at the resi-
dence of a subject, ri[y′] at a date, y′, from one unit of
pollutant emitted from all the vehicles on the road net-
work, some of whose emissions may have started their
airborne travel several hours earlier. To complete the
calculation of D, the received exposure is divided by the
average number of cars per km on the roadway, T(y′). In
this paper, any imputation of Eq. 3 that is needed for a
study subject in year, y′, is done on the transfer function,
D(y′), as long as data for ε() and T() are available. D-
values tend to be roughly constant over historical time,
changing only as the relative traffic pattern changes in
different parts of the modeling region. In addition to de-
pending on the road network, D-values depend on
region-specific meteorological factors that enter the
transport dispersion model.
Incompleteness index
As previously stated, due to incompleteness in reported
residence addresses and gaps in available historical ex-
posure data, most epidemiologic studies cannot be
expected to have a complete, individualized lifetime dose
for every subject. We wish to assess the potential impact
on estimates of associations between exposure and effect
measures of filling these gaps with imputed values. To
this end we define in Equation 4 an, “incompleteness
index,” as the group-level imputed dose expressed as a
percentage of the total dose:
Incompleteness ¼ PDI
¼ 100%  imputed dose componentð Þ
imputed dose componentþmodeled dose component




Our approach is to use this incompleteness index
(PDI) to define subsets of participants with varying con-
tributions of group level components. Thus, we might
compare regression or correlation results for a subset of
study subjects with PDI’s = 0 to larger subsets with PDI's
less than 20, 30, 40%, and so on. If the results are robust,
with means and confidence limits that suggest a similar
association, we can have confidence that imputation is
not introducing artificial findings. Extrapolation of the
results to the full sample of study subjects would be-
come reasonable. Chi-square analysis of Tables of cases
and controls grouped by intervals of PDI is a simple way
to test for differential bias in imputation percentage.
It would also be reasonable to define an alternate in-
completeness index based on the percentage of time that
imputation was needed for a subject. However, this
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tive an index as the percentage of dose imputed, particu-
larly in situations where historical exposures varied
greatly over time. A major advantage of setting a numer-
ical value of PDI as a limit is that it insures that all study
subjects have their degree of imputation constrained. In
any case, PTI should be computed along with the PDI as
a sensitivity check.
Imputation of gaps in an individual’s dose
For the type of study we are considering, there are
boundaries in space and time separating regions where
individualized exposure estimates can be made. Yet,
some exposure is likely to have occurred outside these
boundaries, necessitating group level surrogates for
these regions. Surrogates should be consistent at the
boundaries such that averages and variances of exposure
match the comparable quantities for subjects with indi-
vidualized exposure. For instance, consider a situation
where reliable local traffic and emission data were not
available before 1960. Suppose that the number of regis-
tered vehicles in a state is taken as the group level surro-
gate for exposure prior to 1960. For consistency, when
the surrogate is extended to a year when it is not
needed, e.g., 1960, it should have the same average as
the individualized exposures that were computed for
1960. This consistency can be accomplished by scaling
the surrogate by the average individualized exposure in
1960, dose(1960), and dividing by the vehicle registration
number in 1960, as in Equation 5.




To individualize the surrogate in Eq. 5 for study sub-
ject, i, the surrogate has been multiplied by a random
variable, V1(i), which is uniquely chosen for each study
subject in each imputed data set. The distribution of V1
should be chosen to have a mean of unity and a vari-
ance that matches the variance in 1960 of the individu-
alized exposure estimates. For purposes of allowing
sensitivity analysis, we have added a parameter, k1, as
an exponent in Eq. 5, which could be varied around
unity, should one want to test regressions with health
data for different assumptions about the relationship
between early vehicle registration numbers and traffic
exposure. Standardization of the surrogate is carried
out separately for cases and controls. Although Eq. 5 is
independent of geographic locations of residences, it
would also be possible to perform the analysis separ-
ately by geographical subregions of the study area.
A surrogate like the one defined in Equation 5 is the
very opposite of an individualized dose, which impliesconsiderable possible misclassification. And, the surro-
gate is likely to be highly correlated with age, requiring
careful control of the age-variable to avoid residual
confounding. On the other hand, if exposure is particu-
larly important at young ages, then exposures in the
period requiring surrogates is likely to be important.
Also, it is quite possible that increased cancer incidence
with age is due in part to the longer time older people
have to accumulate exposure and to develop cancer [23].
A middle ground position would be to compare regres-
sion coefficients with and without the early dose surro-
gate included. When included, the implicit assumption
is that early dose effects are so strong biologically that
an exposure estimate grossly misclassified at the individ-
ual level will still be adequate to improve the overall
dose classification, thereby facilitating the detection of
any effect. Excluding the early dose surrogate is equiva-
lent to assuming a biologic model that has cancer risk
from the exposure falling off in importance years after
exposure.
The early surrogate cannot contribute directly to any
recall bias, because no information from interview plays
a role in its initial calculation. Recall bias could never-
theless carry over to the early surrogate, however, be-
cause the scaling factor which is computed separately by
cases and controls is based on post-1960 individualized
data that depends on subject recall of address locations.
For some of the numerical examples given in this paper,
we exclude the early dose surrogate, because including it
does not help us elucidate potential recall bias using the
PDI, which is a major focus of the paper.
It may not always be possible to find a boundary on
which to match a surrogate. This is the case for subjects
during periods when they resided within the temporal
boundaries of the study, but outside the spatial regions.
The natural way to generate dose surrogates for these
subjects during their out-of-area periods is to retain as
much data needed for individual calculations as applies
outside the spatial region, but use average values for
non-available parameters. The needed average values
can be computed by summing over the individualized
values calculable for study subjects inside the spatial
study area during the same time period.
There is no a-priori reason for expecting the averages
to be the same in and outside the region, so we multiply
the results by a common sensitivity parameter, k2, which
can be varied in regressions with health data to check
the importance of the default assumption that the aver-
ages are the same. Let, F(t, p1, p2, p3, p4), be an individu-
alized exposure at time, t, for a subject residing inside
the study area, given values of the parameters, p1, p2, p3,
and p4. Assume that p3 and p4 are unknown for study
subjects outside of the area. Then, the surrogate for a
time when a subject, i, is out of the study area, becomes:
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where p3 and p4 have been replaced by < p3 > and < p4>,
averages over values for other study subjects, namely
those subjects residing in the study area at time, t. Once
again, individualization can be carried out by multiplying
by a random variable with mean unity, which we call,V2.
The variance of V2 would be chosen to match the vari-
ance of subjects with individualized doses inside the
study area. With this surrogate, the variance, V2, can
change over time, so that matching needs to be carried
out more than once, say, every five years. As with the
earlier surrogate, standardization is done separately for
cases and controls.
We note that the parameter, k2, could also serve as a
regression coefficient to be determined as part of the re-
gression with health data. An alternate approach would
be to individualize the parameters < p3 > and < p4 > separ-
ately. See supplementary information for a discussion of
these options.
The two group-level surrogates defined above refer to
dose accumulated over different time periods in a
subject's life. Obtaining an individual's imputed dose re-
quires summing over both, if both are non-zero.
Imputation of missing residence information
There may be additional imputation required for a study
subject, even within the temporal and spatial boundaries
of the main study, for instance, to impute an individual-
ized, D-value or other indicator of local exposure. In our
example, historical street addresses, including house
number, were obtained by interview, which meant rely-
ing on the memory of study subjects for input to
geocoding software. Additional file 1: Figure S1-1 shows
the percentage of geocoding success by year of arrival at
residence. For 1960, the success rate was 65%; therefore,
35% of the addresses in that year needed imputation.
We consider two ways to carry out the imputation on
the theory that having two methods to compare regres-
sion results is a safeguard. Consistent results have the
potential to increase confidence in the outcome; incon-
sistent results would be a warning that the imputation
approach was problematic.
Within the mathematical function that defines short-
term exposure there will be some residence indicator,
whether it be proximity to roads or a meteorological
transfer function specific to a residence, such as the D-
values discussed earlier. When a quantity like D is miss-
ing, the easiest method of imputation, suggested by
Raaschou-Nielsen et al. [5] is to interpolate between
values at residences before and after the missing value.
To obtain values that differ between different imputeddata sets, we can multiply the interpolated imputed ex-
posure quantity by a random number with a log normal
distribution whose variance is obtained from a lognor-
mal fit to the two calculable quantities about which one
is interpolating. For each imputed data set, a distinct
value is randomly drawn from the derived lognormal
distribution. Alternatively, when there is a missing
quantity at starting or stopping dates, extrapolation can
be used. In such a case, zero variance is assigned to the
lognormal distribution and there is, therefore, no differ-
ence in interpolated dose component for a study sub-
ject in different imputed data sets for the missing
residence period.
This method has the advantage that it relies solely on
individual information and does not require the use of
covariates in helping to choose the imputed dispersion
coefficient. It has the disadvantage that, if there is a long
tail in the exposure distribution, it can overstate the im-
puted exposure components when one of those high
values is used for imputation.
Our second method relies on the fact that when infor-
mation on residence location is obtained by question-
naire, it is likely that most residents will be able to
remember at least the city, town, or village of the resi-
dence, even if they are not able to remember the full ad-
dress. This means their location can be narrowed; in the
US, we have found location could be narrowed to the
Census Division Place level 80% of the time in our ex-
ample study. Thus, it is possible to narrow the imput-
ation to values of the observed data within the
corresponding Place. In what follows, we call this, “im-
putation by place.” To handle the situation when a cen-
sus division cannot be assigned or when the number of
either cases or controls in a census Place is less than five
(11% of locations in our example study), it is appropriate
to fall back on the interpolation method.
With imputation by place, it is good practice to use
covariates available for a subject, such as income or edu-
cation, in picking the imputed values, because they could
have influenced the area chosen for a residence. One of
the limitations of multiple imputation is that there are
situations involving missingness not at random that can
introduce bias. This possibility can be reduced by in-
cluding a large number of covariates in the imputation
model, thereby increasing the chances that any variables
predictive of missing values are incorporated [15].
Observed values of covariates included in the
imputation-by-place algorithm for our breast cancer ex-
ample were D, smoking status (passive and active), edu-
cation, history of fertility problems, history of benign
breast disease, family history of breast cancer, combined
estrogen receptor and progesterone receptor status
among cases, parity, BMI, dietary intake of PAH, lifetime
intakes of grilled or barbecued and smoked meats,
Figure 1 Major roads from which emissions were tracked. Study
participants came from the area on the island marked off with bold
boundaries, 150-km in length. The transect defines the location of
the predicted air concentrations shown in Figure 2. Long Island
Breast Cancer Study Project, 1996–1997 [26].
Figure 2 Relative 1-hour air concentrations modeled for 1995
along a transect across Nassau County, Long Island. The origin
is at the ocean side of the transect shown in Figure 1. Long Island
Breast Cancer Study Project, 1996–1997 [26].
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trol status was also included, which at first consideration
seems circular; however, including it is a valid part of
multiple imputation [24,25]. Otherwise, patterns in the
observed data might not be transferred to the unob-
served data during imputation.
In contrast to imputation by interpolation, which may
overestimate high values of dose, when there is a highly
right-skewed distribution, the method of imputation by
place may overestimate some low values of dose, should
the values in the top tail of the distribution be correlated
with the density of road intersections, as would be
expected. This contrasting tendency makes use of the
two methods in regression of health outcomes a useful
test of the robustness of results.
Breast cancer example
Study population
We use data on 3,064 female breast cancer cases and
controls who were residents of Long Island, New York,
between August, 1996, and July, 1997 [26]. Cases were
women newly diagnosed with a first primary in situ or
invasive breast cancer; controls under 65 were identified
through random digit dialing and by Health Care Fi-
nance Administration (HCFA) rosters for those 65 years
of age and older. Controls were frequency matched to
the expected age distribution of cases.
Residence locations on Long Island, but not outside of
Long Island, were identified at the time of the in-person,
structured interview, starting with a subject’s earliest recol-
lection. This resulted in a total of 8,319 locations in Nassau
and Suffolk counties divided among the 3,064 women. Ad-
dress coordinates at the street level were identifiable for
5,383 of these locations using commercial geocoding soft-
ware (BLR Inc., now part of GDT, Lebanon, NH), with 95%
of the remainder identifiable only to the 5-digit Census cat-
egory, “Place,” due to incomplete address information. A
census division, “Place,” consists of consolidated cities and
incorporated places, such as town or village. Certain
unincorporated areas may also be assigned a Place num-
ber http://www.census.gov/geo/www/codes/place/down-
load.html. The average population of a study-area Place in
the 1990 Census was approximately ten thousand, or
about 1% of the total population of Long Island. Location
to the Place level is sufficient to capture the urbanization
gradient along the length of the elongated Island study
area [18]. For consistency, the street maps used for
geocoding were used to model dispersion of traffic pollu-
tion. The study area and surrounding traffic network are
shown in Figure 1. Relative 1-hour air concentrations pre-
dicted by the geographic dispersion model in 1995 along a
transect across Long Island are shown in Figure 2.
Benzo(a)pyrene (BaP) emitted from vehicle tailpipes
was the pollutant proxy analyzed for the numericalexamples, because there is an abundance of good histor-
ical data [21]. The emission per km variable, ε(y’), in
Eq. 3 peaked in the US in the mid-1970s, declining rap-
idly with the introduction of catalytic converters until
the late 1980s [21]. This means that per unit of time, ex-
posure in the pre-1980 period was likely to be much
higher than after 1985, adding large temporal variation
to the spatial variation associated with proximity to traf-
fic evident in Figure 2.
Data for BaP and other PAH tailpipe emissions extend
back only to 1960, which sets that year as a boundary
for shifting to group level information. In the absence of
information, and no engineering reason evident in the
literature to think otherwise, we took ε(y′) to be a
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1960. We also took the dispersion variable, D, as con-
stant, equal to the average value computed in 1960
for residences in the study area. We used vehicle reg-
istrations in New York State, for which date existed
back to 1900, as the surrogate for traffic flow rates
for the pre-1960 period, as in Eq. 5. See Additional
file 1: Figure S1-2.The LIBCSP meteorological dispersion model
The LIBCSP meteorological dispersion model was devel-
oped specifically for the Long Island Breast Cancer
Study Project's analysis of traffic exposures, although it
has been adapted for use in the Buffalo, New York area,
with separate tests carried out in that region [19,27]. A
special feature of the model is its allowance for separate
emissions from road intersections, which are known to
be higher than during cruise emissions [28,29]. The
model does not account for street canyon effects, but
that is not a necessity for Long Island.
The contribution from each road segment to the air
concentration at a downwind receptor residence was
computed within 100 meters of a road using a highway
line-source model [30] applied to each of the 500,000,
straight-line road segments in the traffic network. The
“Chock” highway model was chosen because it gave the
best fit, when compared to a suite of models tested, to
tracer concentrations near the Long Island Expressway
as part of a test carried out by the New York Depart-
ment of Environmental Protection [31]. R2 values ranged
from 0.75 to 0.92 for various meteorological conditions
and angles to the road.
Beyond 100 meters, we used a standard Gaussian puff
dispersion model (equivalent to the USEPA’s “RAM“
model [32]). Additional file 2: Table S2-3 describes the
default parameters and data sources used in the disper-
sion model. Further details can be found in the text of
Additional file 2, including an explanation of the ap-
proach used to shift between different meteorological
models at 100 meters and a description of how we ac-
count for background BaP blown into the study area
from outside it.
Total concentration at a study subject’s residence was
computed as the sum of the contributions from the ap-
proximately 500,000 source segments. This concentra-
tion at a residence forms the basis for the transfer
function, D.
The transport model used to compute the transfer
function, D, was previously validated against BaP soil mea-
surements at approximately 500 residences [18]. A key
result was higher than average emissions coming from
traffic intersections, which were modeled separately. See
Additional file 1: Figure S1-3 for a graphic showingseparately-modeled intersection regions superimposed on
a segment of the road network.Imputation to account for missing residence location in
the Long Island example
Imputation is needed during times when subjects reside
in the study area, but their residence location is not
known with enough precision to determine accurate lati-
tudes and longitudes, quantities that are necessary to ob-
tain individualized exposure. In the example data
presented in this paper, the primary method of imput-
ation used was imputation by place. We imputed a D-
value from the set of D’s calculated for other women res-
iding in the same census division Place. The choice of
imputed values was conditioned on the observed covari-
ates discussed earlier using fully conditional specification
as implemented in the R-program, “Multivariate Imput-
ation by Chained Equations (MICE)” [33]. MICE is but
one of a number of imputation programs available in
statistics computer packages. Fifteen different sets of
data were calculated with missing transfer functions and
any missing covariates imputed. For further details of
the example imputation, see text in Additional file 2.
The input to the imputation program is a matrix file
with "NA"s for missing transfer functions and missing
covariates; the output is a set of files with the NAs re-
placed with numeric values, which generally differ from
set to set. Because of the long-tailed distribution found
in exploratory analysis (see Figure 3), there was no
standard distribution, e.g., lognormal, that could be used
to fill the missing transfer functions. Therefore, we ran
the MICE program with the option to sample randomly
from D-values fully calculable for other subjects. These
samplings are not completely random, however; the pro-
gram uses regression techniques to weight the choices
according to any tendency of different transfer functions
to cluster by covariates. The output files are then avail-
able for regression against health data and the variance
of the results between imputed data sets plays a role in
determining confidence limits using standard rules [14].Results
The main results from this paper are Eqs. 2, 3, 4, 5, 6
and the approaches we described to operationalize them.
In this section, we discuss results from the Long Island
example.
Different biological effectiveness functions: For the illus-
trative example, Pearson correlation coefficients between
dose calculated with different biological effectiveness fac-
tors ranged from 0.33 to 0.79 with no limits set on PDI
(PDI < = 100%). The range was 0.59 to 0.99 for complete-
case analysis (PDI = 0). See Table 1 and Additional file 1:
Tables S1-1 and S1-2.
Figure 3 Normal probability plots of cumulative dose from
1960 through 1995. With and without intersection dose, both with
percentage of dose imputed (PDI) < = 90%, N = 2211. 95%
confidence limits shown. Relative dose units: 1 unit = 1 year's
average dose in 1995. Long Island Breast Cancer Study Project,
1996–1997 [26].
Beyea et al. Environmental Health 2013, 12:62 Page 9 of 13
http://www.ehjournal.net/content/12/1/62Early surrogate dosage (before 1960)
The early surrogate dosage for the breast cancer study
subjects averaged 50% of the post-1960 dose (calcu-
lated for the B1, constant sensitivity biologic model).
Additional file 1: Figure S1-4 graphs the average de-
pendency on age. The Pearson correlation coefficient
was 0.6.
There was essentially zero correlation between the early
surrogate and the cumulative dose post-1960. The Pear-
son correlation coefficient ranged from −0.05 to 0.001 as
the limit on PDI ranged from 0 to 100%. This low correl-
ation means that inclusion of the early surrogate in the dose
summation could alter the distribution curve for total dose.Table 1 Pearson correlation coefficients between doses comp
effectiveness factor, averaged over 15 imputationsa
Samples of women limited by allowed percentage of imputed dose (PD
Dose surrogate CCA (PDI = 0%)
N: 547
Cumulative dose 1960-1995
Dose for 1995 only (Promoter model) 0.59 (0.11)
Peak annual dose in 1960–1995 (Threshold model) 0.99 (0.00)
Cumulative dose X (onset age)-2 (Age sensitive model)b 0.89 (0.024)
Pre-1960 surrogatec −0.020
aNumbers in parenthesis are the square root of the variance across imputations div
deviation of the average over imputations.
bWeighting based on the mathematical fit to radiation risks of excess breast cancer
cCalculated for one imputation only.Doses calculated after 1960 (Zcalc and Zimp)
Of the 2,986 study subjects who arrived in the study area
before 1996, about 55% of them arrived after 1960. Thus,
individually modeled doses in the post-arrival period
(Zcalc) are strongly affected by arrival date because late
arrivers are missing their out-of-area contribution. Pear-
son correlation coefficient with year of arrival = −0.37.
Figure 4a graphs the relationship, showing how the Zcalc,
post-arrival doses fall off for late arriving study subjects.
Without accounting for out-of-area exposure through
imputation, i.e., by adding the Zimp contribution, false
differences in dose calculations can arise, should cases
and controls, because of unmeasured covariates, have a
different distribution of arrival times.
The Zimp surrogate itself, like Zcalc, is highly correlated
with year of arrival, albeit with a different sign (Pearson
coefficient = 0.56). Figure 4b shows how adding the post-
arrival, out-of-area surrogate, Zimp, to the individualized
dose component, Zcalc, removes the dependence on year
of arrival.
To avoid interpreting BaP as more than a PAH
proxy [34], doses are presented in the Figures, not in
units of inhaled milligrams of BaP, but in units of the
1995 average dose computed for women in the study
area. Note that Figures 4a and 4b show graphs for
but one imputed data set; however, the patterns are
virtually identical at this level of detail for 14 add-
itional imputed data sets, as is to be expected given
the great variance around the mean dose curve (results
not shown). Also note that a dose value in Figure 4b may
be the sum of three terms, an out-of-area imputation, an
in-area imputation, and a geographically modeled
component.
Although adding Zcalc and Zimp together eliminates
the obvious way that recall bias could enter the esti-
mation of doses, it is still necessary to go further and look
for residual bias in Zcalc + Zimp, which can be done using
the PDI variable. We performed a chi-square analysis ofuted with different functional forms for the biologic
I)
PDI < 20% PDI < 40% PDI < 60% PDI < 80% (PDI < = 100%)
1164 1477 1764 2051 2986
(comparison dose variable)
0.39 (0.15) 0.39 (0.16) 0.39 (0.16) 0.41 (0.16) 0.33 (0.15)
0.93 (0.00) 0.93 (0.00) 0.92 (0.01) 0.91 (0.01) 0.75 (0.017)
0.87 (0.028) 0.85 (0.033) 0.84 (0.039) 0.82 (0.044) 0.79 (0.06)
−0.031 −0.031 −0.030 −0.016 +0.00044
ided by the square root of 15, which provides an estimate of the standard
in atomic bomb survivors.
Figure 4 Dose as a function of year of arrival in study area, with/without pre-arrival surrogate. Relative dose units: 1 unit = 1 year’s
average dose in 1995. Long Island Breast Cancer Study Project, 1996–1997 [26].
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are shown in Table 2. The p-value for rejecting the null hy-
pothesis was 0.13, which is low enough to suggest some as-
sociation between PDI and case status in our illustrative
example, and therefore the possibility of differential bias.Table 2 Distribution of women by limits on incompleteness in
(Women who arrived before 1996)
Limits on PDIa Number of control wom
Zero (complete coverage) 267
>0 and < 20% 336
20% to < 40% 164
40% to < 60% 150
60% to < 80% 136
80% to < = 100% 465
Total 1518
Probability level for Chi-Square
aPDI = Percent of dose imputed.
bThe Chi-square probability level can vary between low (0.04) and high (0.31) valueRight-skewed distribution and a 1% dose tail
The top 1% of the cumulative dose distribution showed
unusually high values associated with doses from
heavily-trafficked intersections, as shown in Figure 3,
where probability plots are presented with and withoutdex (PDIa) in cumulative dose for one imputed data setb









s for different imputed data sets.
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Without intersection dose included, the probability plot
of log dose in Figure 3, with the exception of one point,
trends smoothly below the normal line at the high end.
However, with intersection dose included there is an
abrupt deviation, with points falling well outside the
upper 95% confidence limit on the normal curve shown
in the Figure. The same skewed distribution appears
when plotting doses computed for other assumptions
about the biological effectiveness factor, B, with the ex-
ception of the pure promoter model, B4 (results not
shown). The skewed distribution at high doses was
maintained no matter the limitation placed on imput-
ation percentage (PDI) in 15 imputed data sets (results
not shown).
Discussion
The past decade has seen an increasing understanding of
the importance of the impact on chronic disease risk of
exposures at all stages of life, especially exposures occur-
ring during the early years of life when many organs are
still undergoing rapid and formative growth [17]. Because
many epidemiological studies of chronic illnesses such as
cancer are usually initiated when the study population
have already reached adulthood, capturing decades-old
data on critical factors such as nutrition, exercise, and en-
vironmental exposures is a major challenge.
Residential address histories can be gathered by inter-
view with relative ease, and we previously developed
models for using histories obtained directly from patient
interviews to estimate residential exposure to PAHs
from traffic sources [35,36] which we then calibrated
against environmental measurements for participants in
a breast cancer case–control study [18]. We further re-
fined our methodology and historical database to take
into account long-term changes in emission control
technology [21]. A primary limitation, however, con-
tinues to be the completeness and accuracy of patient
address recall. The present work provides a methodology
to address this type of limitation by applying multiple im-
putation methods to extract the maximum information
from available data, making it possible to use incompletely
known residential data to put credible bounds on expos-
ure metrics.
The early (pre-1960) surrogate dosage for the breast
cancer study subjects averaged 50% of the post-1960
dose, showing that it can make a substantial contribu-
tion to lifetime dosage.b Interestingly, because this surro-
gate prior to scaling does not depend on information
obtained from interview, it cannot directly introduce any
recall bias into the dose estimates, although some bias
can be carried over to it from the post-1960 averages.
The way the early surrogate is defined in our example,
without separate standardization by geographic region,the only connection to an individual is through age.
However, the weak association (p = 0.13) between PDI
and case status in our breast cancer data implies pos-
sible differential bias due to missing residential data;
this will be investigated in a forthcoming epidemio-
logical analysis that uses the present method to predict
breast cancer risk.
Our finding of a consistent, strongly right-skewed distri-
bution of traffic doses, associated with heavily trafficked
intersections, means that non-standard distributions of ex-
posure must be anticipated in studying traffic emissions.
And, for our example data, this high-dose subpopulation
is worthy of attention in future risk analyses that include
these study subjects.
Because Pearson correlation coefficients between dose
calculated with different biological effectiveness factors
ranged from 0.33 to 0.79 with no limits set on PDI (PDI < =
100), the sensitivity of risk to age at exposure could be im-
portant in determining the strength of an association with
health outcome; moreover, it suggests that regressions
against health data might shed some light on which biologic
model is most appropriate.
Conclusions
In historical reconstructions of exposure, investigators
typically identify data that have been collected for envir-
onmental monitoring and not for epidemiology, and that
do not fully cover the population of interest. We suggest
here a way of filling in missing data that we hope will
spur increased use of historical exposure reconstruction
in health studies. A novel feature of our exposure recon-
struction approach is an incompleteness index (PDI)
that can be used to study the degree to which imput-
ation might create artifactual dosages and, subsequently,
improper associations with health outcomes -- a form of
differential bias to which researchers need to be sensitive
in general [37,38] and specifically in traffic air pollution
studies [39].
Endnotes
aThe risk equation in the main text, Eq. 1, was consid-
ered to be linear in dose. If the log odds is considered to
be non-linear in exposure, then there would be terms in
powers of Z as well a term in the log of Z [23,40,41] and
possibly powers of log of Z. We did not consider such
an extension of the methodology in the examples given
in this paper.
bOne way to reduce the relative contribution of the
early surrogate would be to trade one approximation
for another, namely running the full exposure model
at times earlier than the period for which full emis-
sions and traffic data exists. This extrapolation could
introduce misclassification due to errors in traffic
flow rates and tailpipe emission rates, but might introduce
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on an early surrogate. Depending on the variability in
a model, an analyst might explore extrapolating the
individualized model back in time to reduce the con-
tribution from the early dose surrogate to a modest
level relative to total dose.
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